Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared to the conference in 2025, consistent with expanding global adoption of OGM. Key highlights from studies of OGM presented at ESHG 2026: 35 studies featured OGM — a 67% increase over the 21 studies reported at ESHG 2025.

GlobeNewsWire • Jun 18, 2026

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that demonstrate the utility of optical genome mapping (OGM) for the detection and characterization of structural variants (SVs) in studies of reproductive health and prenatal genetic disorders. Reproductive disorders including infertility and recurrent pregnancy loss are highly prevalent and very often carry a genetic component.

GlobeNewsWire • Jun 11, 2026

Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?

Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Jun 8, 2026

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "Debentures"). The Company used cash on hand to retire the Debentures, which were originally issued in May 2024 in the aggregate face value of $20,000,000.

GlobeNewsWire • May 28, 2026

Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors

Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Investment Research • May 28, 2026

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM's potential to transform how this aggressive blood cancer is studied and understood.

GlobeNewsWire • May 26, 2026

Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 13, 2026

Bionano Reports First Quarter 2026 Results and Provides a Business Update

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community," commented Al Luderer, Ph.D.

GlobeNewsWire • May 13, 2026

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $1.15 per share a year ago.

Zacks Investment Research • May 13, 2026

Bionano Announces Leadership Transition

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May 5, 2026. Dr. Luderer will continue to serve as chairman, and director Chris Twomey will serve as Lead Independent Director. He succeeds Erik Holmlin, PhD, who is staying on as an advisor. The company anticipates a seamless transition without business disruption.

GlobeNewsWire • May 6, 2026